At the time of writing, Larimar Therapeutics Inc [LRMR] stock is trading at $3.58, down -1.38%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LRMR shares have gain 10.15% over the last week, with a monthly amount drifted -10.72%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Larimar Therapeutics Inc [NASDAQ: LRMR] stock has seen the most recent analyst activity on October 16, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $26. Previously, Wedbush started tracking the stock with Outperform rating on October 03, 2024, and set its price target to $22. On October 02, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $15 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $16 on September 04, 2024. Leerink Partners initiated its recommendation with a Outperform and recommended $25 as its price target on April 03, 2024. Citigroup upgraded its rating to Buy for this stock on November 17, 2023, but kept the price target unchanged to $4.50. In a note dated October 19, 2022, Guggenheim initiated an Buy rating and provided a target price of $12 on this stock.
For the past year, the stock price of Larimar Therapeutics Inc fluctuated between $3.01 and $13.68. Currently, Wall Street analysts expect the stock to reach $17 within the next 12 months. Larimar Therapeutics Inc [NASDAQ: LRMR] shares were valued at $3.58 at the most recent close of the market. An investor can expect a potential return of 374.86% based on the average LRMR price forecast.
Analyzing the LRMR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.36 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.49 points at the first support level, and at 3.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.73, and for the 2nd resistance point, it is at 3.87.
Ratios To Look Out For
It is important to note that Larimar Therapeutics Inc [NASDAQ:LRMR] has a current ratio of 13.10. Also, the Quick Ratio is 13.10, while the Cash Ratio stands at 2.15.
Transactions by insiders
Recent insider trading involved Hamilton Thomas Edward, Director, that happened on Feb 16 ’24 when 57208.0 shares were purchased. Director, Flynn James E completed a deal on Feb 16 ’24 to buy 4.29 million shares. Meanwhile, Director THOMAS FRANK E bought 2000.0 shares on Feb 14 ’24.
